05/12/23 7:00 AMNasdaq : SLGL earningsSol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate UpdatePositive trends continue for TWYNEO ® and EPSOLAY ® with recurrent prescriber base s at 98% for TWYNEO and 92% for EPSOLAY during Q1 2023 Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Phase 1 trial for SGT-210RHEA-AIneutral
03/20/23 7:00 AMNasdaq : SLGL conferences Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an innovative pipeline, today announced that it will present at H.C. Wainwright’s Autoimmune &RHEA-AIneutral
03/10/23 7:00 AMNasdaq : SLGL earningsSol-Gel Reports Full-Year 2022 Financial Results and Corporate DevelopmentsRecent acquisition of Phase 3-ready SGT-610 ( p atidegib ) , an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome A Phase 3 study of SGT-610 is expected to initiate in the second half of 2023,RHEA-AIpositive
01/27/23 7:29 AMNasdaq : SLGL Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement OfferingsSol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a dermatology company with FDA approvals for EPSOLAY ® and TWYNEO ®, two innovative dermatology products that were launched in the U.S. by partner Galderma during 2022,RHEA-AIneutral
01/27/23 7:00 AMNasdaq : SLGL acquisitionclinical trialSol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 MillionPatidegib, an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, if approved by the FDA Phase 3 study expected to initiate in the second half of 2023, with results expected by the end of 2025RHEA-AIpositive
11/10/22 4:00 AMNasdaq : SLGL earningsSol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateSol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatologyRHEA-AIpositive
10/03/22 8:00 AMNasdaq : SLGL managementSol-Gel Technologies Appoints Michael Glezin Vice President, Business DevelopmentSol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today the appointment ofRHEA-AIvery positive
08/04/22 6:00 AMNasdaq : SLGL earningsSol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateP rescription volumes to date indicate strong uptake, similar to successful dermatology launches Sol-Gel r eceives $3.5 million milestone payment from commercial partner Galderma Holding SA (“Galderma”) for FDA approval of EPSOLAY Sol-Gel’s cash runway expected to extend through the end of 2023RHEA-AIvery positive
06/01/22 8:00 AMNasdaq : SLGL conferencesSol-Gel Technologies to Participate in the 2022 Jefferies Global Healthcare ConferenceSol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, today announced that ChiefRHEA-AIneutral
05/17/22 7:00 AMNasdaq : SLGL conferencesSol-Gel Technologies to Present in Upcoming H.C. Wainwright Global Investment ConferenceSol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, today announced that that theRHEA-AIneutral